The efficacy of BRAF/MEK inhibitor therapy for ALM, particularly with the BRAF V600E mutation has been explored in various studies, Jiang et al. demonstrated that treatment with the BRAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib resulted in significant tumor responses and improved progression-free survival in patients with ALM and BRAF V600E mutations [50]. This evidence concerns the gene MAP2K7 and acral lentiginous melanoma.